Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

283
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
283
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

354
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
354
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

173
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
173

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maternal exposure to titanium dioxide nanoparticles disrupts ultrasonic vocalization development in mouse offspring.

Particle and fibre toxicology·2026
Same author

Brain Monoamine Deficits in the CD Mouse Model of Williams-Beuren Syndrome.

Biomolecules·2025
Same author

5-HT6 receptors: Contemporary views on their neurobiological and pharmacological relevance in neuropsychiatric disorders.

Dialogues in clinical neuroscience·2025
Same author

Cingulate cortex stimulation drives distinct pupillary responses in rat via recruitment of noradrenergic neurons in the locus coeruleus.

Cerebral cortex (New York, N.Y. : 1991)·2025
Same author

Developmental alterations of indirect-pathway medium spiny neurons in mouse models of Huntington's disease.

Neurobiology of disease·2025
Same author

Widespread and Heterologous Effects of L-DOPA on Monoaminergic Tissue Metabolism in Newborn Rats Expressing Air-Stepping.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Jul 13, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.8K

Limiting Monoamines Degradation Increases L-DOPA Pro-Locomotor Action in Newborn Rats.

Inès Khsime1, Marie Boulain1, Abderrahman Fettah1

  • 1Univ. Bordeaux, CNRS, INCIA, UMR5287, F-33000 Bordeaux, France.

International Journal of Molecular Sciences
|October 14, 2023
PubMed
Summary

Inhibiting monoamine degradation enhances L-DOPA

Keywords:
L-DOPAair-steppingmonoaminesnewborn ratspinal cord

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.8K
Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease
10:09

Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease

Published on: February 14, 2012

51.2K

Related Experiment Videos

Last Updated: Jul 13, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.8K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.8K
Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease
10:09

Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease

Published on: February 14, 2012

51.2K

Area of Science:

  • Neuroscience
  • Developmental Biology
  • Pharmacology

Background:

  • L-DOPA (Levodopa) is a precursor to catecholamines and promotes locomotion in vertebrates.
  • Early post-natal development involves critical monoamine system maturation.
  • Understanding factors that enhance L-DOPA's pro-locomotor effects is crucial for developmental neuroscience.

Purpose of the Study:

  • To investigate if inhibiting monoamine degradation can potentiate the pro-locomotor action of a low L-DOPA dose in five-day-old rats.
  • To determine the role of monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) inhibition in modulating L-DOPA-induced locomotion.
  • To correlate biochemical changes in spinal monoamine levels with observed locomotor activity.

Main Methods:

  • Administered nialamide (MAO inhibitor) or tolcapone (COMT inhibitor) to five-day-old rats.
  • Assessed locomotor activity by measuring air-stepping sequences in a harness.
  • Quantified monoamine and metabolite levels in the cervical and lumbar spinal cord tissue.

Main Results:

  • Neither nialamide nor tolcapone alone induced significant locomotion.
  • Both nialamide (100 mg/kg) and tolcapone (100 mg/kg) maximally enhanced air-stepping when co-administered with a sub-effective L-DOPA dose (25 mg/kg).
  • Inhibitor efficacy was confirmed by regional changes in specific monoamine levels within the spinal cord.

Conclusions:

  • Inhibiting the degradation of monoamines significantly boosts the pro-locomotor effect of low-dose L-DOPA in young rats.
  • Different monoamine environments, achieved through distinct enzyme inhibition, can lead to maximal locomotor responses.
  • This suggests that modulating monoamine metabolism is a viable strategy to enhance L-DOPA's therapeutic potential in developmental contexts.